N- (3- (1H- indol- 4- yl)- 5- (2- methoxyisonicotinoyl)phenyl)methanesulfonamide

an antimitotic agent; structure in first source

Also Known As:

LP 261; LP-261; LP261 cpd

Networked: 3 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Isonicotinic Acids: 144
      - N-(3-(1H-indol-4-yl)-5-(2-methoxyisonicotinoyl)phenyl)methanesulfonamide: 3
- Heterocyclic Acids
  - Isonicotinic Acids: 144
    - N-(3-(1H-indol-4-yl)-5-(2-methoxyisonicotinoyl)phenyl)methanesulfonamide: 3
Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - N-(3-(1H-indol-4-yl)-5-(2-methoxyisonicotinoyl)phenyl)methanesulfonamide: 3
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - N-(3-(1H-indol-4-yl)-5-(2-methoxyisonicotinoyl)phenyl)methanesulfonamide: 3

Experts

1.	Figg, William D: 1 article (02/2012)
2.	Gardner, Erin R: 1 article (02/2012)
3.	Kelly, Martha: 1 article (02/2012)
4.	Lee, Kyoung-jin: 1 article (02/2012)
5.	Li, Haiqing: 1 article (02/2012)
6.	Moore, William: 1 article (02/2012)
7.	Springman, Eric: 1 article (02/2012)
8.	Bukhtiyarova, Marina: 1 article (01/2011)
9.	Chao, Wenchun: 1 article (01/2011)
10.	Dorsey, Bruce D: 1 article (01/2011)

Related Diseases

1.	Neoplasms (Cancer) 02/01/2012 - "Oral LP-261 is very effective at inhibiting tumor growth in multiple mouse xenograft models and is well tolerated." 01/13/2011 - "An optimized lead LP-261 significantly inhibits growth of a human non-small-cell lung tumor (NCI-H522) in a mouse xenograft model." 02/01/2012 - "Combining oral, low dose LP-261 with bevacizumab led to significantly improved tumor inhibition. "
2.	Prostatic Neoplasms (Prostate Cancer) 02/01/2012 - "LP-261 was tested as a single agent in colon adenocarcinoma (SW620) and prostate cancer (LNCaP and PC3) xenografts, evaluating several different dosing schedules. "
3.	Influenza in Birds (Avian Flu) 06/01/2008 - "(+)-Dapoxetine hydrochloride, (R)-Etodolac; Abatacept, ABT-510, Adalimumab, Agatolimod sodium, Alemtuzumab, Alvocidib hydrochloride, Aminolevulinic acid methyl ester, Aripiprazole, AS01B, AS02B, AS02V, Azacitidine; Becatecarin, Bevacizumab, Bevirimat, Bortezomib, Bremelanotide; CAIV-T, Canfosfamide hydrochloride, CHR-2797, Ciclesonide, Clevidipine; Darbepoetin alfa, Decitabine, Degarelix acetate, Dendritic cell-based vaccine, Denosumab, Desloratadine, DMXB-Anabaseine, Duloxetine hydrochloride, Dutasteride; Ecogramostim, Eicosapentaenoic acid/docosahexaenoic acid, Eletriptan, Enzastaurin hydrochloride, Erlotinib hydrochloride, Escitalopram oxalate, Etoricoxib, Everolimus, Ezetimibe, Ezetimibe/simvastatin; Ferumoxytol, Fesoterodine fumarate, Fulvestrant; Gefitinib, GM-CSF DNA, GSK-690693; H5N1 avian flu vaccine, Hepatitis B hyperimmunoglobulin, Human Fibroblast Growth Factor 1, Hypericin-PVP; Icatibant acetate, Iclaprim, Immunoglobulin intravenous (human), Ipilimumab, ISS-1018; L19-IL-2, Lapuleucel-T, Laropiprant, Liposomal doxorubicin, LP-261, Lumiracoxib, LY-518674; MDV-3100, MGCD-0103, Mirabegron, MyoCell; NASHA/Dx, Niacin/laropiprant; O6-Benzylguanine, Ocrelizumab, Olmesartan medoxomil, Omalizumab; P-276-00, Paclitaxel nanoparticles, Paclitaxel nanoparticles, Padoporfin, Paliperidone, PAN-811, Pegaptanib octasodium, Pegfilgrastim, Pemetrexed disodium, PF-00299804, Pimecrolimus, Prasugrel, Pregabalin; Reolysin, Rimonabant, Rivaroxaban, Rosuvastatin calcium; Satraplatin, SCH-697243,Selenite sodium, Silodosin, Sorafenib, Sunitinib malate; Talarozole, Taxus, Temsirolimus, Tocilizumab, Tolevamer potassium sodium, Tremelimumab, TTP-889; Uracil; V-260, Valsartan/amlodipine besylate, Vardenafil hydrochloride hydrate, Varenicline tartrate, Varespladib, Vitespen, Voclosporin, VX-001; Xience V; Zotarolimus-eluting stent."
4.	Colonic Neoplasms (Colon Cancer) 02/01/2012 - "LP-261 was tested as a single agent in colon adenocarcinoma (SW620) and prostate cancer (LNCaP and PC3) xenografts, evaluating several different dosing schedules. "

Related Drugs and Biologics

1.	Bevacizumab (Avastin)
2.	Ferrosoferric Oxide (Magnetite)
3.	Simvastatin (Zocor)
4.	Hepatitis B Vaccines (Hepatitis B Vaccine)
5.	Amlodipine (Norvasc)
6.	Etodolac (Lodine)
7.	Paclitaxel (Taxol)
8.	Intravenous Immunoglobulins (IVIG)
9.	Fibroblast Growth Factor 1 (FGF-1)
10.	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)

Related Therapies and Procedures

1.	Stents